Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers
Autor: | Homira Behbahani, Jan Kehr, Vesna Jelic, Walid Tajeddinn, Takashi Yoshitake, Micha Milovanovic, Dag Aarsland, Angel Cedazo-Minguez, Tasmin Shahnaz, Seyed-Mohammad Fereshtehnejad, Kina Höglund, Petter Järemo, Bengt Winblad, Mohammed Seed Ahmed |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Blood Platelets Male medicine.medical_specialty Serotonin Neurology Amyloid tau Proteins Disease Gastroenterology Statistics Nonparametric 03 medical and health sciences 0302 clinical medicine Cerebrospinal fluid Alzheimer Disease Internal medicine medicine Humans Platelet Cognitive Dysfunction Chromatography High Pressure Liquid Psychiatric Status Rating Scales Amyloid beta-Peptides business.industry General Neuroscience General Medicine Electrochemical Techniques Hydroxyindoleacetic Acid Peptide Fragments Psychiatry and Mental health Clinical Psychology P-Selectin 030104 developmental biology Immunology Csf biomarkers Biomarker (medicine) Female Geriatrics and Gerontology business 030217 neurology & neurosurgery |
Zdroj: | Journal of Alzheimer's disease : JAD. 53(2) |
ISSN: | 1875-8908 |
Popis: | Introduction Serotonin (5-HT) is involved in the pathology of Alzheimer's disease (AD). Objective We aimed to measure 5-HT level in platelets in AD and explore its association with cerebrospinal fluid (CSF), AD biomarkers (amyloid-β 1-42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau)), and clinical symptoms. Methods 15 patients with AD and 20 patients with subjective cognitive impairment (SCI) were included. 5-HT metabolites were measured, in a specific fraction, using high performance liquid chromatography with electrochemical detection (HPLC-ECD). Results Significantly lower 5-HT concentrations were observed in AD patients compared to SCI patients both after normalization against total protein (p = 0.008) or platelet count (p = 0.019). SCI patients with lower 5-HT level have higher AD CSF biomarkers, total tau (p = 0.026) and tau/Aβ42 ratio (p = 0.001), compared to those with high 5-HT levels. Conclusion AD patients have reduced platelet 5-HT levels. In SCI, lower 5-HT content was associated with a higher AD-CSF biomarker burden. |
Databáze: | OpenAIRE |
Externí odkaz: |